Re-appraisal of N2 disease by lymphatic drainage pattern for non-small-cell lung cancers: By terms of nodal stations, zones, chains, and a composite

Lung Cancer ◽  
2011 ◽  
Vol 74 (3) ◽  
pp. 497-503 ◽  
Author(s):  
Hui Zheng ◽  
Lin-mao Wang ◽  
Fang Bao ◽  
Ge-ning Jiang ◽  
Hui-kang Xie ◽  
...  
Surgery Today ◽  
2002 ◽  
Vol 32 (4) ◽  
pp. 300-304 ◽  
Author(s):  
Kazuhiro Ueda ◽  
Yoshikazu Kaneda ◽  
Kouichi Saeki ◽  
Nobuhiro Fujita ◽  
Nobuya Zempo ◽  
...  

2017 ◽  
Vol 35 (25) ◽  
pp. 2960-2974 ◽  
Author(s):  
Mark G. Kris ◽  
Laurie E. Gaspar ◽  
Jamie E. Chaft ◽  
Erin B. Kennedy ◽  
Christopher G. Azzoli ◽  
...  

Purpose The panel updated the American Society of Clinical Oncology (ASCO) adjuvant therapy guideline for resected non–small-cell lung cancers. Methods ASCO convened an update panel and conducted a systematic review of the literature, investigating adjuvant therapy in resected non–small-cell lung cancers. Results The updated evidence base covered questions related to adjuvant systemic therapy and included a systematic review conducted by Cancer Care Ontario current to January 2016. A recent American Society for Radiation Oncology guideline and systematic review, previously endorsed by ASCO, was used as the basis for recommendations for adjuvant radiation therapy. An update of these systematic reviews and a search for studies related to radiation therapy found no additional randomized controlled trials. Recommendations Adjuvant cisplatin-based chemotherapy is recommended for routine use in patients with stage IIA, IIB, or IIIA disease who have undergone complete surgical resections. For individuals with stage IB, adjuvant cisplatin-based chemotherapy is not recommended for routine use. However, a postoperative multimodality evaluation, including a consultation with a medical oncologist, is recommended to assess benefits and risks of adjuvant chemotherapy for each patient. The guideline provides information on factors other than stage to consider when making a recommendation for adjuvant chemotherapy, including tumor size, histopathologic features, and genetic alterations. Adjuvant chemotherapy is not recommended for patients with stage IA disease. Adjuvant radiation therapy is not recommended for patients with resected stage I or II disease. In patients with stage IIIA N2 disease, adjuvant radiation therapy is not recommended for routine use. However, a postoperative multimodality evaluation, including a consultation with a radiation oncologist, is recommended to assess benefits and risks of adjuvant radiation therapy for each patient with N2 disease. Additional information is available at www.asco.org/lung-cancer-guidelines and www.asco.org/guidelineswiki .


2007 ◽  
Vol 25 (8) ◽  
pp. 393-401 ◽  
Author(s):  
Koji Takahashi ◽  
William Stanford ◽  
Edwin Van Beek ◽  
Brad Thompson ◽  
Brian Mullan ◽  
...  

2020 ◽  
Author(s):  
Shahan Mamoor

Non-small cell lung adenocarcinoma (NSCLC) is a leading cause of death in the United States and worldwide (1, 2). We mined published microarray data (3, 4, 5) to discover genes associated with NSCLC. We identified significant differential expression of the tyrosine kinase TEK in tumors from patients with NSCLC. TEK may be of relevance to the initiation, progression or maintenance of non-small cell lung cancers.


Author(s):  
Sajad Khan ◽  
Shahid Ali ◽  
Muhammad

Background:Lung cancers or (Bronchogenic-Carcinomas) are the disease in certain parts of the lungs in which irresistible multiplication of abnormal cells leads to the inception of a tumor. Lung cancers consisting of two substantial forms based on the microscopic appearance of tumor cells are: Non-Small-Cell-Lung-Cancer (NSCLC) (80 to 85%) and Small-Cell-Lung-Cancer (SCLC) (15 to 20%).Discussion:Lung cancers are existing luxuriantly across the globe and the most prominent cause of death in advanced countries (USA & UK). There are many causes of lung cancers in which the utmost imperative aspect is the cigarette smoking. During the early stage, there is no perspicuous sign/symptoms but later many symptoms emerge in the infected individual such as insomnia, headache, pain, loss of appetite, fatigue, coughing etc. Lung cancers can be diagnosed in many ways, such as history, physical examination, chest X-rays and biopsy. However, after the diagnosis and confirmation of lung carcinoma, various treatment approaches are existing for curing of cancer in different stages such as surgery, radiation therapy, chemotherapy, and immune therapy. Currently, novel techniques merged that revealed advancements in detection and curing of lung cancer in which mainly includes: microarray analysis, gene expression profiling.Conclusion:Consequently, the purpose of the current analysis is to specify and epitomize the novel literature pertaining to the development of cancerous cells in different parts of the lung, various preeminent approaches of prevention, efficient diagnostic procedure, and treatments along with novel technologies for inhibition of cancerous cell growth in advance stages.


2011 ◽  
Vol 10 (1) ◽  
pp. 26
Author(s):  
Nam Jin Yoo ◽  
Min Sung Kim ◽  
Sug Hyung Lee

Sign in / Sign up

Export Citation Format

Share Document